Literature DB >> 9141436

Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia.

B L Shneider1, V L Fox, K B Schwarz, C L Watson, M Ananthanarayanan, S Thevananther, D M Christie, W Hardikar, K D Setchell, G Mieli-Vergani, F J Suchy, A P Mowat.   

Abstract

The recent cloning of a human sodium-dependent bile acid transporter (NTCP) permits analysis of its expression in human liver disease and investigation of potential primary defects in its expression. NTCP from normal human liver (NHL) was first characterized in detail. Northern blotting of RNA from NHL revealed a 1.8-kb NTCP transcript. Western blotting of crude NHL plasma membranes using a carboxyterminal antipeptide antibody showed that NTCP is a 39-kd polypeptide that is N-glycosylated to a final molecular weight of 56 kd. Indirect immunofluorescent analysis of NHL sections indicated that the NTCP protein is expressed on the basolateral surface of hepatocytes. We hypothesized that the clinical phenotype of a defect in NTCP might be hypercholanemia in the relative absence of liver disease. Accordingly, the coding region of the NTCP gene of two children with this phenotype was sequenced after reverse transcription/polymerase chain reaction (RT/PCR) amplification. No primary defects in the deduced NTCP amino acid sequence were found. Despite the extremely high serum bile salt levels (235 and 126 micromol/L) in these two patients, NTCP messenger RNA (mRNA) and protein expression were quantitatively normal, in contrast to the published observations in a rat model of cholestasis secondary to common bile duct ligation. Hepatic steady-state NTCP mRNA levels in a group of 23 pre- and postportoenterostomy biliary atresia patients were inversely related to total bilirubin, indicating that extrahepatic bile duct obstruction leads to down-regulation of NTCP mRNA levels, similar to that observed in rat common bile duct ligation. Therefore the lack of down-regulation in the two patients with hypercholanemia indicates that elevated serum bile salts are not sufficient to down-regulate NTCP expression, these two patients have abnormal responses to hypercholanemia, or these two patients have a defect in a gene other than NTCP that influences hepatic clearance of bile salts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141436     DOI: 10.1002/hep.510250521

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice.

Authors:  Julia Yue Cui; Lauren M Aleksunes; Yuji Tanaka; Zidong Donna Fu; Ying Guo; Grace Liejun Guo; Hong Lu; Xiao-Bo Zhong; Curtis D Klaassen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-01-19       Impact factor: 4.052

4.  N-Linked Glycosylation Is Not Essential for Sodium Taurocholate Cotransporting Polypeptide To Mediate Hepatitis B Virus Infection In Vitro.

Authors:  Jiwon Lee; Li Zong; Alexander Krotow; Yanli Qin; Lucy Jia; Jiming Zhang; Shuping Tong; Jisu Li
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

5.  Cysteine 96 of Ntcp is responsible for NO-mediated inhibition of taurocholate uptake.

Authors:  Umadevi Ramasamy; M Sawkat Anwer; Christopher M Schonhoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-07-25       Impact factor: 4.052

6.  Evaluating the structural complexity of isomeric bile acids with ion mobility spectrometry.

Authors:  Xueyun Zheng; Francesca B Smith; Noor A Aly; Jingwei Cai; Richard D Smith; Andrew D Patterson; Erin S Baker
Journal:  Anal Bioanal Chem       Date:  2019-05-16       Impact factor: 4.142

7.  Nitric oxide-mediated inhibition of taurocholate uptake involves S-nitrosylation of NTCP.

Authors:  Christopher M Schonhoff; Umadevi Ramasamy; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-25       Impact factor: 4.052

Review 8.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

9.  PKC{epsilon}-dependent and -independent effects of taurolithocholate on PI3K/PKB pathway and taurocholate uptake in HuH-NTCP cell line.

Authors:  Christopher M Schonhoff; Ai Yamazaki; Simon Hohenester; Cynthia R L Webster; Bernard Bouscarel; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-08       Impact factor: 4.052

10.  Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Authors:  John D Clarke; Petr Novak; April D Lake; Rhiannon N Hardwick; Nathan J Cherrington
Journal:  Liver Int       Date:  2017-02-07       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.